Most Likely Diagnosis: Amyotrophic Lateral Sclerosis (ALS)
The clinical presentation of a 60-year-old male with progressive weakness, dysarthria, left-sided proximal weakness, hyperreflexia (biceps), and weakness of quadriceps with decreased tendon reflexes is most consistent with Amyotrophic Lateral Sclerosis (ALS), demonstrating the hallmark combination of upper motor neuron (UMN) and lower motor neuron (LMN) signs.
Diagnostic Reasoning
Key Clinical Features Supporting ALS
The patient exhibits the pathognomonic mixed UMN and LMN pattern 1:
Upper Motor Neuron Signs:
- Hyperreflexia of the biceps
- Spasticity (implied by the hyperreflexia pattern)
Lower Motor Neuron Signs:
- Progressive weakness and muscle wasting
- Decreased patellar tendon reflexes
- Proximal muscle weakness
Bulbar Involvement:
- Dysarthria (slurred speech)
- This indicates brainstem motor neuron involvement
Age and Presentation Pattern
The 60-year-old age matches the typical ALS presentation, with mean onset around 60 years for sporadic ALS 1. The limb-onset pattern (approximately two-thirds of ALS cases) with proximal weakness and concurrent bulbar symptoms fits the expected disease trajectory 1.
Critical Distinguishing Feature
The simultaneous presence of hyperreflexia (UMN) and decreased reflexes (LMN) in different muscle groups is the key diagnostic clue. This mixed pattern of UMN and LMN dysfunction affecting multiple spinal segments without alternative explanation strongly suggests ALS 2.
Acute Management Approach
Immediate Assessment Priorities
Respiratory Function Evaluation:
- Assess vital capacity and respiratory muscle strength immediately
- Monitor for signs of respiratory failure (the ultimate cause of death in ALS)
- Do not delay treatment waiting for confirmatory tests 3
Bulbar Function Assessment:
- Evaluate swallowing safety given dysarthria
- Risk of aspiration with dysphagia
Diagnostic Confirmation
Required Testing:
- Electromyography (EMG) to demonstrate widespread denervation and fasciculations across multiple spinal segments 4
- Exclude ALS-mimics through appropriate investigations 1:
Brain MRI Findings:
- May show T2-weighted hyperintensities along pyramidal tracts 2
Therapeutic Interventions
Pharmacologic Treatment:
- Initiate Riluzole - the only medication proven to extend survival in ALS 1
Supportive Care (Multidisciplinary):
- Early referral to neurology/ALS specialist
- Non-invasive ventilation planning (prolongs survival and improves quality of life) 1
- Speech therapy for dysarthria and swallowing evaluation
- Physical/occupational therapy for weakness management
- Nutritional support planning given bulbar involvement
Critical Pitfalls to Avoid
Do Not Miss These ALS-Mimics:
- Cervical spondylotic myelopathy (can present with mixed UMN/LMN signs but typically has sensory findings)
- Multifocal motor neuropathy (pure LMN, no bulbar involvement)
- Kennedy's disease (X-linked, slower progression)
- Myasthenia gravis (fluctuating weakness, no UMN signs) 4
Common Diagnostic Errors:
- Attributing asymmetric weakness solely to stroke (stroke would not explain the mixed UMN/LMN pattern or progressive course) 5
- Delaying respiratory assessment until diagnosis confirmed 3
- Missing the significance of mixed reflex patterns in different muscle groups
Prognosis Discussion
The prognosis is poor with limb-onset ALS typically progressing to death from respiratory failure within 3-5 years 1. Bulbar symptoms developing early (as in this case with dysarthria) may indicate faster progression, as bulbar-onset cases typically survive 2-3 years 1.
Early intervention with supportive care and Riluzole provides the best opportunity to extend survival and maintain quality of life.